Αρχική World News Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in Low...

Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in Low PD-L1–Expressing Gastric, Gastro-oesophageal Junction, or Oesophageal Adenocarcinoma

Although current recommendations suggest that immune checkpoint inhibitors (ICIs) may be used for all patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma in the first-line setting, the analyses of previously unpublished data from pivotal phase III randomised studies fail to demonstrate a survival advantage when adding ICIs to conventional chemotherapy in patients with low PD-L1–expressing tumours. According to Dr. Raghav Sundar and colleagues of the National University Cancer Institute and National University of Singapore, who published their findings on 3 December 2021 in the Journal of Clinical Oncology, these findings provide the basis to initiate a more detailed reassessment in the selection of treatment options for first-line metastatic gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma.

The authors wrote in the background that ICIs have recently demonstrated significant survival benefit in combination with chemotherapy in the first-line treatment of advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma in CheckMate-649 and KEYNOTE-590 studies. Based on these results, the US Food and Drug Administration (FDA) has granted regulatory approval for the use of nivolumab in the first-line treatment of all advanced gastro-oesophageal adenocarcinomas and pembrolizumab for oesophageal and gastro-oesophageal junction carcinoma. More recently, the FDA has also granted regulatory approval for the addition of pembrolizumab to chemotherapy and trastuzumab for HER2–positive gastric cancer. 

PD-L1 expression measured by calculating the combined positive score (CPS) from immunohistochemistry was studied as a predictive biomarker in these studies. Regulatory approval for nivolumab, however, was granted regardless of PD-L1 status. The efficacy of the nivolumab-chemotherapy combination compared with standard chemotherapy regimens is evident in patients with high PD-L1–expressing tumours, but the efficacy in patients with low PD-L1–expressing tumours is unclear. Data presented thus far from these studies focus on the presentation of all randomly assigned populations and PD-L1–positive (CPS ≥ 1 or ≥ 5 or 10) populations. Forest plots have not informed several clinically relevant PD-L1 subgroups. Therefore, it remains unclear if the survival benefit in all randomly assigned populations is driven largely by the benefit in PD-L1 CPS–positive patients.

In their analysis, the researchers from Singapore tried to elucidate unreported treatment outcomes in low PD-L1–expressing tumours by deriving individual patient survival data, reconstructed from the reported Kaplan-Meier (KM) plots. A graphical reconstructive algorithm was adopted to estimate time-to-event outcomes from reported overall survival (OS) and progression-free survival (PFS) KM plots describing overall or subgroup cohorts. Using reconstructed time-to-event outcomes, KMSubtraction conducts bipartite matching of patients from the reported subgroup among the overall cohort. By excluding matched patients, KM plots and survival analyses of the unreported subgroups were retrieved.

CheckMate-649, KEYNOTE-062, and KEYNOTE-590 were included in the analysis. Two PD-L1 subgroups were identified with data unreported in the primary manuscripts: PD-L1 CPS 1-4 from CheckMate-649 and PD-L1 CPS 1-9 from KEYNOTE-062. No significant differences in OS and PFS were demonstrated in ICI-chemotherapy combinations when compared with chemotherapy among CheckMate-649 PD-L1 CPS 1-4 (OS hazard ratio [HR] 0.950, 95% confidence interval [CI] 0.747 to 1.209, p = 0.678; PFS HR 0.958, 95% CI 0.743 to 1.236, p = 0.743) and KEYNOTE-062 PD-L1 CPS 1-9 subgroups. In the KEYNOTE-062 PD-L1 CPS 1-9 subgroup, patients treated with pembrolizumab had an increased hazard of tumour progression (HR 2.092, 95% CI 1.661 to 2.635, p < 0.001).

By using a novel workflow, KMSubtraction, data of PD-L1 subgroups previously unreported by primary manuscripts were retrieved for pivotal randomised phase III studies. The authors concluded that the results suggest the lack of benefit when adding ICIs to chemotherapy in low PD-L1–expressing gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma.

Dr Sundar was supported by the National Medical Research Council; as part of the Singapore Gastric Cancer Consortium, the study was also partially funded by the NMRC Open Fund-Large Collaborative Grant.


Zhao JJ, Yap DWT, Chan YH, et al. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. JCO; Published 3 December 2021. DOI: 10.1200/JCO.21.01862



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...